• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

350
64
46
44
20

COUNTRY

43
11
5
5
4

PRICE

191
452
667
1,244

PUBLISHED

34
158
388
1,244

PRODUCT TYPE

1,212
17
11
4

Central Nervous System

In 2012 major changes might revolutionize the treatment of multiple sclerosis, as Gilenya, the first novel drug in five years, will be joined by three new products: BG-12, Aubagio, and Lemtrada. Recent exciting developments in drug discovery might also enhance the hopes of those fighting against Alzheimer.

Great commercial and scientific opportunities are to be found in similar battles against a range of diseases and neurodegenerative disorders, e.g. Parkinson’s disease, schizophrenia, migraine, insomnia, epilepsy, etc.

A wide selection of industry reports, scientific journals and academic textbooks in this section allow readers to explore every conceivable facet of this industry, such as market trends, industry forecasts, new drugs in development, the latest research & development, patent applications, and licensing strategies.

Key players featured in our publications include Biogen Idec, Sanofi, Genzyme, and many more. Show Less
Read more

PRODUCT TITLE

EpiCast Report: Migraine - Epidemiology Forecast to 2023

EpiCast Report: Migraine - Epidemiology Forecast to 2023 Summary Migraine is typically characterized by recurring headaches, throbbing pain on one side of the head along with one or more of the following...

February 2014
FROM

Mental Health and Work: United Kingdom

Tackling mental ill-health of the working-age population is becoming a key issue for labour market and social policies in OECD countries OECD governments increasingly recognise that policy has a major...

February 2014
FROM

Batten Disease - Pipeline Review, H1 2014

Batten Disease - Pipeline Review, H1 2014 Summary Global Markets Direct’s, 'Batten Disease - Pipeline Review, H1 2014', provides an overview of the indication’s therapeutic pipeline. This report provides...

January 2014
FROM

Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014

Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014 Summary Global Markets Direct’s, 'Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014', provides an overview of the indication’s therapeutic...

January 2014
FROM

Mental Health and Work: Switzerland

Tackling mental ill-health of the working-age population is becoming a key issue for labour market and social policies in OECD countries OECD governments increasingly recognise that policy has a major...

January 2014
FROM

General Anxiety Disorder - Pipeline Review, H2 2013

General Anxiety Disorder - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'General Anxiety Disorder - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

December 2013
FROM

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2013

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review,...

December 2013
FROM

Hypoxic-Ischemic Encephalopathy - Pipeline Review, H2 2013

Hypoxic-Ischemic Encephalopathy - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Hypoxic-Ischemic Encephalopathy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic...

December 2013
FROM

Progressive Supranuclear Palsy - Pipeline Review, H2 2013

Progressive Supranuclear Palsy - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Progressive Supranuclear Palsy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic...

December 2013
FROM

Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2013

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2013', provides an overview of the...

December 2013
FROM

Hyperalgesia - Pipeline Review, H2 2013

Hyperalgesia - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Hyperalgesia - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

December 2013
FROM

Peripheral Neuropathic Pain - Pipeline Review, H2 2013

Peripheral Neuropathic Pain - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Peripheral Neuropathic Pain - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic...

December 2013
FROM

Circadian Rhythm Sleep Disorders - Pipeline Review, H2 2013

Circadian Rhythm Sleep Disorders - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Circadian Rhythm Sleep Disorders - Pipeline Review, H2 2013', provides an overview of the indication’s...

December 2013
FROM

Degenerative Disc Disease - Pipeline Review, H2 2013

Degenerative Disc Disease - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Degenerative Disc Disease - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

December 2013
FROM

Tauopathies - Pipeline Review, H2 2013

Tauopathies - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Tauopathies - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

December 2013
FROM

Child Abuse Global Clinical Trials Review, H2, 2013

Child Abuse Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Child Abuse Global Clinical Trials Review, H2, 2013" provides data on the Child Abuse clinical trial scenario....

December 2013
FROM

Friedreich Ataxia Global Clinical Trials Review, H2, 2013

Friedreich Ataxia Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Friedreich Ataxia Global Clinical Trials Review, H2, 2013" provides data on the Friedreich Ataxia clinical...

December 2013
FROM

Parkinson's Disease Therapeutics Market to 2019 - Pipeline Shows Shift Towards Long Term Disease Management

The Parkinson’s Disease (PD) market is dominated by symptomatic treatments targeting functional impairment in PD Levodopa has remained the gold standard treatment for almost 40 years and has significantly...

December 2013
FROM

Alzheimer's Pipeline Drugs Review, Alzheimer's Disease Drug Market & Forecast – Global Analysis

Alzheimer's disease drug market is on the curvature stage Since 2003, there is not any single “magic bullet” launched in the market to prevent or cure it However, all current marketed products are going...

December 2013
FROM

Spinal Stenosis - Pipeline Review, H2 2013

Spinal Stenosis - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Spinal Stenosis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

November 2013
FROM
Loading Indicator

Our Clients

Our clients' logos